Press Releases
May 21, 2009
Waxman amendment on safety at Santa Monica Airport included in H.R. 915, FAA Reauthorization Bill
Rep. Waxman continues to work with the Chairman of the House Transportation and Infrastructure Committee to pressure the Federal Aviation Administration (FAA) to achieve runway safety area solutions consistent with FAA design guidelines to address the safety concerns at Santa Monica Airport.
Mar 31, 2009
Chairmen Waxman, Markey Release Discussion Draft of New Clean Energy Legislation
Chairman Henry A. Waxman of the Energy and Commerce Committee and Chairman Edward J. Markey of the Energy and Environment Subcommittee released a draft of clean energy legislation that will create jobs, help end our dangerous dependence on foreign oil, and combat global warming. The American Clean Energy and Security Act of 2009 (ACES) is a comprehensive approach to America’s energy policy that charts a new course toward a clean energy economy.
Mar 27, 2009
Chairman Waxman Releases GAO Report Highlighting Need for Better Data on Healthcare Associated Infections
Issues: Health
Reps. Henry A. Waxman, Frank Pallone, Jr., and Shelley Berkley released a new Government Accountability Office (GAO) report highlighting the need for nationwide data on the risk of healthcare associated infections in ambulatory surgical centers (ASCs).
Mar 13, 2009
Energy and Commerce Committee Announces Investigation into Bayer CropScience Explosion
Issues: Health
The Committee on Energy and Commerce Chairman Henry A. Waxman and Subcommittee on Oversight and Investigations Chairman Bart Stupak announced an investigation into the August 28, 2008, explosion at the Bayer CropScience facility in Institute, West Virginia.
Mar 11, 2009
Bipartisan Group of Members Introduces “Promoting Innovation and Access to Life-Saving Medicines Act”
Issues: Health
Reps. Henry A. Waxman, Frank Pallone, Nathan Deal, and Jo Ann Emerson introduced H.R. 1427, the “Promoting Innovation and Access to Life-Saving Medicine Act,” a bipartisan bill to allow the Food and Drug Administration to approve affordable copies of biotech drugs. Biotech drugs, while often life-saving, are the fastest growing and most expensive components of the nation’s prescription drug bill. Many of them cost tens of thousands of dollars a year — prices that put them out of reach of patients and impose an unsustainable burden on employers, insurers, and the federal government.
Mar 5, 2009
Health Leaders Introduce Legislation Reversing Supreme Court's Medical Device Decision
Issues: Health
U.S. Reps. Frank Pallone, Jr. (D-NJ), Chairman of the Energy and Commerce Subcommittee on Health, and Henry A. Waxman (D-CA), Chairman of the Energy and Commerce Committee, today introduced legislation in the House that will reverse a U.S. Supreme Court decision that denies injured patients the ability to seek compensation for their injuries and gives medical device makers blanket immunity.
Mar 4, 2009
Energy and Commerce Committee Passes Landmark Family Smoking Prevention and Tobacco Control Legislation
Issues: Health
The Energy and Commerce Committee approved H.R. 1256, the “Family Smoking Prevention and Tobacco Control Act,” by a vote of 39 to 13. This legislation will give FDA the authority to prevent the dangerous and all-too prevalent marketing and sales of tobacco to children.
Feb 4, 2009
Chairman Waxman Announces Commerce Department Estimate That Over Two Million Households are on DTV Coupon Waiting List
As of February 3, 2009, the Commerce Department estimates that over two million households are currently on the waiting list for over 3.6 million converter box coupons.
Jan 8, 2009
Chairman Waxman Announces Energy and Commerce Committee Subcommittee Chairs and Membership
The Democratic Caucus of the House Committee on Energy and Commerce made subcommittee selections for the 111th Congress.
Oct 30, 2008
Chairman Waxman Releases GAO Report on Federal Oversight of Part D Drug Pricing
Issues: Health
Chairman Henry A. Waxman released a new GAO report titled “Medicare Part D Prescription Drug Coverage: Federal Oversight of Reported Price Concessions Data.” The report finds that the Centers for Medicare & Medicaid Services (CMS) has only conducted half of the scheduled audits of drug pricing information reported by the Part D plans.
